Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Provided By GlobeNewswire

Last update: Jan 22, 2025

VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.